EVALUATION OF THE LONG-TERM EFFECTS OF INTRAOPERATIVE USE OF A CARRIER-BOUND FIBRIN SEALANT (TachoSil®). SHOULD WE CONTINUE USING IT? A RETROSPECTIVE STUDY idicarlo@unict.it

195-07

EVALUATION OF THE LONG-TERM EFFECTS OF INTRAOPERATIVE USE OF A CARRIER-BOUND FIBRIN SEALANT (TachoSil®). SHOULD WE CONTINUE USING IT? A RETROSPECTIVE STUDY

4

 

 

 

 

Italy

Oral or Poster

This study analyses the long-term effects of a carrier-bound fibrin sealant (CBFS) after abdominal surgery by following up patients years after application.

Sex, age, type of disease (related to the affected organ), indications for surgery, and type of surgical procedure were also studied. The site of CBFS application during the procedure was reported. From 2006 to 2022, all patients who underwent this procedure were contacted telephonically. All patients with previously significant images and those who underwent computed tomography (CT) scans were included to evaluate the actual situation of the matrix.

During the study period, a total of 40 patients (33 [82.5%] men and 7 [17.5%] women) aged 32–87 years, with a mean age of 67.8 years, were included. The indications for surgery were hepatocellular carcinoma, 23 (57.5%); hydatid cyst, 3 (7.5%); hepatic adenoma, 1 (2.5%); hepatic trauma, 2 (5.0%); cholecystitis, 2 (5.0%); splenic rupture or bleeding for trauma, 3 (7.5%); neuroendocrine tumour, 1 (2.5%); trauma of the pancreas, 1 (2.5%); peptic gastric ulcer, 3 (7.5%); and colon cancer, 1 (2.5%). Surgery was performed in 6 (15.0%) cases using the laparoscopic approach and in the remaining 34 (85.0%) cases by laparotomy. After 11 years of follow-up, CBFS was observed in four patients on CT.

Our results showed that CBFS can be permanent years after the procedure. We cannot affirm any secondary effect, but we can affirm that CBFS sponges are not resorbed in 12 weeks and can remain many years after implantation.